Recursion Gross Profit from 2010 to 2025

RXRX Stock

USD 6.73 0.00 0.00%

Recursion Pharmaceuticals Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Recursion Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2020-03-31

Previous Quarter

14 M

Current Value

-8.3 M

Quarterly Volatility

11.1 M

Covid

Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.9 M, Interest Income of 16.5 M or Depreciation And Amortization of 38.3 M, as well as many indicators such as Price To Sales Ratio of 29.93, Dividend Yield of 0.0 or PTB Ratio of 1.88. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Recursion Pharmaceuticals Correlation against competitors.

For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Latest Recursion Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Recursion Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Recursion Pharmaceuticals minus its cost of goods sold. It is profit before Recursion Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Recursion Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Recursion Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (300.82 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Recursion Gross Profit Regression Statistics

	Arithmetic Mean	(29,350,622)
	Geometric Mean	26,388,374
	Coefficient Of Variation	(87.17)
	Mean Deviation	22,253,645
	Median	(44,098,000)
	Standard Deviation	25,584,455
	Sample Variance	654.6T
	Range	74.2M
	R-Value	0.75
	Mean Square Error	303.6T
	R-Squared	0.57
	Significance	0.0008
	Slope	4,046,913
	Total Sum of Squares	9818.5T

Recursion Gross Profit History

	2025	14.3 M
	2024	13.6 M
	2023	2 M
	2022	-8.6 M
	2021	10 M
	2020	-59.9 M

Other Fundumenentals of Recursion Pharmaceuticals

Gross Profit Margin

Recursion Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Common Stock
Total Assets		0.98	0.88	-0.92	-0.97	0.94	0.16	0.93	0.3	0.98	0.89	0.89	0.86	0.97	0.94	0.83	0.92	0.9	-0.85	-0.85	-0.85	0.79
Total Stockholder Equity	0.98		0.95	-0.91	-0.95	0.89	0.02	0.88	0.1	1.0	0.81	0.91	0.89	0.92	0.95	0.83	0.87	0.84	-0.78	-0.78	-0.78	0.73
Net Tangible Assets	0.88	0.95		-0.9	-0.87	0.71	-0.28	0.69	-0.1	0.95	0.59	0.93	0.93	0.79	0.94	0.8	0.69	0.63	-0.58	-0.58	-0.58	0.54
Net Debt	-0.92	-0.91	-0.9		0.9	-0.77	0.14	-0.73	-0.29	-0.91	-0.69	-0.95	-0.94	-0.89	-0.95	-0.89	-0.73	-0.69	0.65	0.65	0.65	-0.6
Retained Earnings	-0.97	-0.95	-0.87	0.9		-0.92	-0.12	-0.88	-0.29	-0.96	-0.85	-0.86	-0.82	-0.95	-0.96	-0.87	-0.93	-0.88	0.8	0.8	0.8	-0.78
Accounts Payable	0.94	0.89	0.71	-0.77	-0.92		0.46	0.99	0.38	0.9	0.98	0.71	0.66	0.96	0.82	0.74	0.98	0.99	-0.94	-0.94	-0.94	0.88
Long Term Debt	0.16	0.02	-0.28	0.14	-0.12	0.46		0.49	0.53	0.04	0.59	-0.25	-0.31	0.29	-0.1	-0.06	0.46	0.55	-0.56	-0.56	-0.56	0.51
Net Receivables	0.93	0.88	0.69	-0.73	-0.88	0.99	0.49		0.37	0.89	0.99	0.69	0.65	0.93	0.77	0.67	0.97	0.99	-0.94	-0.94	-0.94	0.88
Total Liab	0.3	0.1	-0.1	-0.29	-0.29	0.38	0.53	0.37		0.11	0.5	0.18	0.14	0.39	0.15	0.27	0.4	0.43	-0.34	-0.34	-0.34	0.5
Net Invested Capital	0.98	1.0	0.95	-0.91	-0.96	0.9	0.04	0.89	0.11		0.82	0.9	0.88	0.92	0.95	0.83	0.87	0.85	-0.79	-0.79	-0.79	0.74
Short Long Term Debt	0.89	0.81	0.59	-0.69	-0.85	0.98	0.59	0.99	0.5	0.82		0.62	0.57	0.92	0.71	0.64	0.96	0.99	-0.95	-0.95	-0.95	0.88
Total Current Assets	0.89	0.91	0.93	-0.95	-0.86	0.71	-0.25	0.69	0.18	0.9	0.62		0.99	0.8	0.9	0.85	0.66	0.63	-0.52	-0.52	-0.52	0.64
Net Working Capital	0.86	0.89	0.93	-0.94	-0.82	0.66	-0.31	0.65	0.14	0.88	0.57	0.99		0.75	0.87	0.8	0.61	0.58	-0.49	-0.49	-0.49	0.57
Short Term Debt	0.97	0.92	0.79	-0.89	-0.95	0.96	0.29	0.93	0.39	0.92	0.92	0.8	0.75		0.91	0.88	0.93	0.93	-0.87	-0.87	-0.87	0.82
Property Plant Equipment	0.94	0.95	0.94	-0.95	-0.96	0.82	-0.1	0.77	0.15	0.95	0.71	0.9	0.87	0.91		0.92	0.81	0.75	-0.69	-0.69	-0.69	0.64
Current Deferred Revenue	0.83	0.83	0.8	-0.89	-0.87	0.74	-0.06	0.67	0.27	0.83	0.64	0.85	0.8	0.88	0.92		0.71	0.67	-0.54	-0.54	-0.54	0.7
Good Will	0.92	0.87	0.69	-0.73	-0.93	0.98	0.46	0.97	0.4	0.87	0.96	0.66	0.61	0.93	0.81	0.71		0.98	-0.92	-0.92	-0.92	0.86
Intangible Assets	0.9	0.84	0.63	-0.69	-0.88	0.99	0.55	0.99	0.43	0.85	0.99	0.63	0.58	0.93	0.75	0.67	0.98		-0.95	-0.95	-0.95	0.89
Long Term Debt Total	-0.85	-0.78	-0.58	0.65	0.8	-0.94	-0.56	-0.94	-0.34	-0.79	-0.95	-0.52	-0.49	-0.87	-0.69	-0.54	-0.92	-0.95		1.0	1.0	-0.7
Capital Surpluse	-0.85	-0.78	-0.58	0.65	0.8	-0.94	-0.56	-0.94	-0.34	-0.79	-0.95	-0.52	-0.49	-0.87	-0.69	-0.54	-0.92	-0.95	1.0		1.0	-0.7
Deferred Long Term Liab	-0.85	-0.78	-0.58	0.65	0.8	-0.94	-0.56	-0.94	-0.34	-0.79	-0.95	-0.52	-0.49	-0.87	-0.69	-0.54	-0.92	-0.95	1.0	1.0		-0.7
Common Stock	0.79	0.73	0.54	-0.6	-0.78	0.88	0.51	0.88	0.5	0.74	0.88	0.64	0.57	0.82	0.64	0.7	0.86	0.89	-0.7	-0.7	-0.7

Click cells to compare fundamentals

About Recursion Pharmaceuticals Financial Statements

Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	13.6 M	14.3 M
Gross Profit Margin	0.23	0.24

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC